Cargando…
Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment
Despite treatment of patients with metastatic colorectal cancer (mCRC) with bevacizumab plus chemotherapy, response rates are modest and there are no biomarkers available that will predict response. The aim of this study was to assess if markers associated with three interconnected cancer-associated...
Autores principales: | Noonan, Sinead A., Morrissey, Maria E., Martin, Petra, Biniecka, Monika, Ó'Meachair, Shane, Maguire, Aoife, Tosetto, Miriam, Nolan, Blathnaid, Hyland, John, Sheahan, Kieran, O'Donoghue, Diarmuid, Mulcahy, Hugh, Fennelly, David, O'Sullivan, Jacintha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828217/ https://www.ncbi.nlm.nih.gov/pubmed/29535825 http://dx.doi.org/10.18632/oncotarget.24276 |
Ejemplares similares
-
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
por: Martin, Petra, et al.
Publicado: (2014) -
Nuclear oxidative damage correlates with poor survival in colorectal cancer
por: Sheridan, J, et al.
Publicado: (2009) -
Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer
por: Murphy, Adrian G., et al.
Publicado: (2016) -
Tumour Tissue Microenvironment Can Inhibit Dendritic Cell Maturation in Colorectal Cancer
por: Michielsen, Adriana J., et al.
Publicado: (2011) -
Characterising the prognostic potential of HLA-DR during colorectal cancer development
por: Dunne, Margaret R., et al.
Publicado: (2020)